Risk factor
Fair trading liquidity
Profitability factor
Greatly overvalued vs peers
About
Medicalsystem Biotechnology Co., Ltd. is a Chinese company focused on delivering clinical diagnostic solutions. Their comprehensive product line includes a full array of reagents and instruments designed for COVID-19 detection, such as PCR, antibody, and antigen test kits, alongside nucleic acid reagents. Beyond infectious disease diagnostics, the company also supplies advanced medical equipment like automated biochemistry analyzers (complete with their corresponding bio-reagents), hematology analyzers, urine analyzers, and glycated hemoglobin analyzers. Additionally, their offerings extend to Point-of-Care Testing (POCT) devices and cutting-edge chemiluminescence immunoassay analyzers. In addition to its diagnostic product offerings, Medicalsystem also provides healthcare services. Initially established in 2003 as Ningbo Medicalsystem Biotechnology Co., Ltd., the company officially adopted its current name, Medicalsystem Biotechnology Co., Ltd., in January 2017. Its corporate headquarters are situated in Ningbo, China.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITDA